exp date isn't null, but text field is
Eli Lilly ceased marketing Olanzapine intramuscular injection (Zyprexa) in the UK for commercial reasons in 2013.
The preparation retains marketing authorisation throughout the rest of the EU.
Consequently, it has to be imported from Europe making the version used technically unlicensed in the UK.
The licensed indications for the original UK version of olanzapine injection still apply i.e. the rapid control of agitation and disturbed behaviour in patients with schizophrenia or in mania, when oral therapy is inappropriate1 and it remains a treatment option within GG&C’s Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour.2
As a treatment option for acutely disturbed behaviour, it is unlikely that prior consent for the use of intramuscular olanzapine could be obtained. In fact, it is the view of the Mental Welfare Commission for Scotland that individuals cannot give advance consent to the potential use of intramuscular medication.3 Adherence to the principles contained in the Adults with Incapacity (Scotland) Act, 2000 and/or Mental Health (Care and Treatment) (Scotland) Act 2003 is mandatory in the case of intramuscular medication for acutely disturbed behaviour.
Due to its unlicensed status, explanation for the rationale of treatment choice should be given at a suitable time during the patient’s treatment.4 Patient information explaining unlicensed medication in general terms is available via Choice and Medication, as is a specific olanzapine leaflet.
The consultant psychiatrist must make a clear record of the rationale for prescribing an unlicensed medication within the patient’s case notes and document the discussion regarding consent.
When ordering olanzapine intramuscular injection, the patient’s initials and CHI should be included on the requisition as well as the phrase "as per protocol" for the order to be processed.
A record of administration of unlicensed medication must be kept (as per unlicensed medication policy).5 This must include drug batch numbers, patient name and CHI number. The comments section of the recording sheet may be used for the purpose of documenting the batch number. It is the responsibility of the nurse in charge to ensure this occurs.
When supplying olanzapine intramuscular injection from pharmacy, pharmacy staff must ensure that batch numbers are documented on the requisition.
• Blood pressure (lying & standing)
• Level of hydration
• Level of consciousness
At least hourly until the patient is ambulatory and there are no concerns about physical health. Monitor more regularly if the patient appears to be asleep or sedated, has taken illicit drugs or alcohol, has a pre-existing physical health problem or has experienced any harm as a result of any restrictive intervention.2
Adults1,8,9,10: 5 – 10mg by intramuscular injection. A repeat dose of 5 – 10mg may be given after a minimum of 2 hours. Maximum daily dose is 20mg (includes any oral olanzapine), with not more than 3 injections in 24 hours. Maximum treatment course is 3 days.
Elderly1,8.9.10: 2.5 – 5mg by intramuscular injection. A repeat dose of 2.5 – 5mg may be given after a minimum of 2 hours. Maximum daily dose is 20mg (includes any oral olanzapine), with not more than 3 injections in 24 hours. Maximum treatment course is 3 days
Adolescents10: 2.5 - 5mg by intramuscular injection (depending on age, weight, previous exposure to antipsychotic medication, and whether has underlying neurodevelopmental disorder/LD). A repeat dose of 2.5 - 5mg may be given after a minimum of 2 hours. Maximum daily dose is 10mg - 20 mg (again dependent on above parameters and including any oral olanzapine), with not more than 3 injections in 24 hours. Maximum treatment course is 3 days.
Common1,8,9,10 ( <1/10 and >1/100): sedation, altered heart rate (tachy and bradycardia), hypotension,
postural hypotension, discomfort at the injection site
Uncommon1,8,9,10 (<1/100 and >1/1000): reduced respiratory rate, abnormal heart rhythms
In addition, the injection shares side effects associated with oral olanzapine (see latest Summary of Product Characteristics11 for full details).
• Hypersensitivity to olanzapine or any other excipients in Zyprexa injection.
• Known narrow angle glaucoma
• Unstable medical conditions e.g. acute MI, unstable angina, severe hypotension
• Concomitant use of benzodiazepines - If the patient is considered to need parenteral benzodiazepine treatment, this should not be given until at least one hour after IM olanzapine administration. If the patient has received parenteral benzodiazepine, IM olanzapine administration should only be considered after careful evaluation of clinical status, and the patient should be closely monitored for excessive sedation and cardio-respiratory depression.
• Dementia related psychosis and/or behavioural disturbance
• Parkinson’s disease
• Neuroleptic Malignant Syndrome
• Hyperglycaemia & diabetes
• Lipid alterations
• Prostatic hypertrophy
• Paralytic ileus
• Hepatic function
• Prolonged QT interval
• Tardive dyskinesia
• Postural Hypotension
Caution should be exercised in patients who consume alcohol or take medicines that can induce hypotension, bradycardia, respiratory or CNS depression
Benzodiazepines – see above
CYP1A2 inducers e.g. smoking, carbamazepine. May lead to reduced olanzapine concentrations.
CYP1A2 inhibitors e.g. fluvoxamine. May lead to increased olanzapine concentrations.
Drugs known to prolong QT interval
1. Summary of Product Characteristics Zyprexa injection. Eli Lilly. Accessed via European Medicines Agency on 8/8/17 www.ema.europa.eu/ema
2. NHS GG&C Mental Health Services. Guideline for use of Intramuscular Medication for Acutely Disturbed Behaviour in Mental Health and Associated Services.MHS 40. April 2016
4. Mental Welfare Commission for Scotland. Advice Notes. Medical Treatment under Part 16 of the Mental Health (Care and Treatment) (Scotland) Act 2003.
5. GMC Good practice in prescribing and managing medicines and devices. Updated Dec14
7. NHS Greater Glasgow and Clyde Area Drug and Therapeutics Committee Policies Relating to the Management of Medicines Section 9.1 Acute Unlicensed Medicines Policy (ULM Policy)
8. Martindale. The Complete Drug Reference. Accessed 8/8/17
9. Bazire S. Psychotropic Drug Directory 2016; Lloyd Reinhold Publications
10. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry; 12th edition: Wiley Blackwell
11. Summary of Product Characteristics Zyprexa. Eli Lilly. Accessed 8/8/17
Last reviewed: 28 June 2019
Next review: 01 October 2020
Approved By: PMG-MH
Reviewer Name(s): Andrew Walker, Suzanne Burke